The developmentally important Hedgehog (Hh) signal transduction pathway, which has recently been implicated in several forms of cancer, is subject to regulation by several protein kinases. Here, we address the role of protein kinase Cd in pathway inhibition and show that cellular depletion or pharmacological inhibition of this kinase isoform results in a blockade of signalling between Suppressor of Fused and the Gli transcription factors. We further provide evidence that the observed pathway inhibition is independent of primary cilia and the mitogen-activated protein kinase kinase (Mek1) kinase. These findings allowed for the rapid dissection of downstream Hh pathway activation mechanisms in human tumour cells and demonstrate a surprising variation in how cells can activate signalling in a ligand-and receptorindependent manner.
The developmentally important Hedgehog (Hh) signal transduction pathway, which has recently been implicated in several forms of cancer, is subject to regulation by several protein kinases. Here, we address the role of protein kinase Cd in pathway inhibition and show that cellular depletion or pharmacological inhibition of this kinase isoform results in a blockade of signalling between Suppressor of Fused and the Gli transcription factors. We further provide evidence that the observed pathway inhibition is independent of primary cilia and the mitogen-activated protein kinase kinase (Mek1) kinase. These findings allowed for the rapid dissection of downstream Hh pathway activation mechanisms in human tumour cells and demonstrate a surprising variation in how cells can activate signalling in a ligand-and receptorindependent manner. Oncogene (2007) 26, 5163-5168; doi:10.1038/sj.onc.1210321; published online 19 February 2007 Keywords: Hedgehog signalling; phorbol ester; protein kinase C The Hedgehog (Hh) signalling pathway comprises an evolutionarily conserved intercellular communication system with important instructive roles in the developing embryo. Compared to the widespread functions during embryogenesis, Hh signalling is restricted in the adult organism where it is implicated in stem cell proliferation and tissue repair (Beachy et al., 2004) . Persistent signalling or inappropriate reactivation results in cellular hyperproliferation and subsequent cancer development.
Three mammalian Hh ligands exist: SHH (Sonic Hh), IHH (Indian Hh) and DHH (Desert Hh), which all bind to their common receptor Patched1 (Ptch1) on the surface of receiving cells. This binding relieves the inhibitory effect Ptch1 exerts upon the G-protein coupled receptor-like protein Smoothened (Smo) . Smo transmits the signal by a currently unclear mechanism to the ultimate effectors of the pathway, the zinc-finger transcription factors Gli2 and Gli3, which then activate target gene transcription. Target genes are, for example, Ptch1 and Hip1 (Hh-interacting protein1), which are thought to sequester Hh ligands and terminate the response via a negative feedback mechanism. Another target gene is Gli1, expression of which is proposed to alter target gene expression from a Gli2-to a Gli1-specific pattern (Eichberger et al., 2006) . Of the three Glis, Gli1 is an obligate activator, Gli2 is mainly an activator and Gli3 is mainly a repressor of transcription. Inhibitors of the pathway include, for instance, the downstream negative factor Suppressor of Fused (Sufu), which directly binds Gli proteins and antagonizes their function.
Another level of complexity in regulation of the Hh pathway is added by the influence of post-translational modifications. Protein kinase A (PKA), casein kinase 1 (CK1), glycogen synthase kinase 3b (GSK3b), DYRK1a, phosphoinositide 3-kinase/Akt and recently the mitogen-activated protein kinase kinase (Mek1) and protein kinase Cd (PKCd) have all been shown to affect mammalian Hh signal transduction (Mao et al., 2002; Pan et al., 2006; Riobo et al., 2006a, b; Sheng et al., 2006; Tempe et al., 2006; Wang and Li, 2006) .
With respect to the latter kinase, at least 10 isoforms are known. They are classified into three classes based on their structure and their activation mechanisms (Liu and Heckman, 1998; Ohno and Nishizuka, 2002) : The 'classical' PKCs, which are calcium-dependent and sensitive to diacylglycerol (DAG) and phorbol ester, include the isoforms a, bI, bII and g. The 'novel' PKC class is calcium-independent and DAG/phorbol estersensitive and contains the d, e, Z and y isoforms. The third group comprises the 'atypical' PKC isoforms (z, l/i), which are calcium and DAG/phorbol esterindependent. The expression pattern of some of these isozymes is complex and varies significantly between different tissues. However, the isoforms a, bI, bII, d, e and z seem to be ubiquitously expressed and can be found in most tissues (Liu and Heckman, 1998) .
As Hh-dependent tumours seem to have activated the pathway at distinct levels, a detailed knowledge about pathway activation routes is of utmost importance to drug development approaches to allow for the correct choice of molecular drug target. Currently, a limited number of non-siRNA experimental tools for blocking the pathway at various levels are available to the research community: antibodies to (Sonic) Hh , Smo-antagonizing small molecules (Cyclopamine and others; Taipale et al., 2000; Frank-Kamenetsky et al., 2002) or the Gliinhibiting PKA activator forskolin (FSK) (Pan et al., 2006; Sva¨rd et al., 2006) . However, none of these reagents is for instance, capable of distinguishing between pathway induction by loss of Sufu and pathway induction by direct Gli activation.
Recently, Riobo et al. (2006a) described the involvement of PKC isoforms in the regulation of the Hh pathway. Short-term treatment of fibroblasts with PKCactivating phorbol esters, such as 12-O-tetradecanoylphorbol 13-acetate (TPA, phorbol 12-myristate 13-acetate (PMA)), resulted in a ligand-independent activation of Hh/Gli signalling. This activation was mediated by PKCd acting via Mek1, and not by PKCa or e (the other phorbol ester-sensitive PKC isoforms expressed by mouse NIH3T3 fibroblasts; Liu et al., 2000) . The authors further demonstrated that Hh signalling requires basal PKCd activity for proper function, since depletion of this PKC isoform by longterm TPA exposure blocked SHH-induced signal transduction in NIH3T3 cells.
This inhibition might occur at the level of the Hh ligand itself or in the receiving cell with, for instance, the potential protein targets Ptch1, Smo, Sufu or the final transcriptional factors Gli1, Gli2 or Gli3. To get insight into the interaction between TPA and the Hh pathway, we began by inducing signalling at the Smo level using the synthetic Smo agonist SAG (Chen et al., 2002) . As can be seen in Figure 1a , TPA treatment for 48 h completely blocked SAG-induced signalling in Shh-L2 cells (Shh-Light2 cells; an NIH3T3 line with a stably integrated Gli luciferase reporter gene (Chen et al., 2002) ). This result points to an inhibition by TPA at the level of Smo or downstream. This finding was confirmed using an endogenous reporter system, i.e. mouse mesenchymal C3H10T1/2 cells, which upregulate Protein kinase Cd in Hedgehog signal transduction M Lauth et al alkaline phosphatase expression upon Hh/SAG stimulation ( Figure 1b) . Next, we sought to extend this analysis by detection of Gli1 expression, a target gene of Hh signalling. A high level of Gli1 mRNA is a reliable signal response of pathway activity. As can be seen in Figure 1c , TPA treatment resulted in a significant reduction of target gene expression in SAG-treated NIH3T3. Consistently, pathway inhibition was also achieved in Ptch1À/À cells, characterized by constitutively active signalling owing to deletion of the inhibitory Ptch1 receptor. Most interestingly, pathway inhibition upon TPA exposure was also seen in SufuÀ/À mouse embryonic fibroblasts (MEFs). In these cells, the negative factor Sufu is genetically ablated, resulting in ligand-independent, cell-autonomous downstream activation of signalling (Sva¨rd et al., 2006) . Cyclopamine, a plant steroidal alkaloid from the corn lily, which directly binds and inactivates Smo, was included as a control reagent. Despite being very effective in inhibiting upstream signals, Gli activation in SufuÀ/À cells was not affected by Cyclopamine as activation occurs downstream of Smo (Figure 1c) .
To strengthen the view of TPA as a downstream inhibitor, we analysed expression of another target gene of the pathway, Hip1. As expected, culturing SufuÀ/À MEFs with phorbol ester significantly reduced Hip1 mRNA and protein levels (Figure 1d and e) , thus placing the observed inhibition genetically downstream of Smo and Sufu.
To elucidate further the interaction between phorbol esters and Hh signalling, we checked if formation or function of primary cilia was affected. These organelles have recently been described as essential for Hh signal reception and transduction (Huangfu et al., 2003) . Furthermore, disruption of primary cilia results in downstream effects such as inhibition of Gli2 function (Haycraft et al., 2005) . Analysis of primary cilia in TPAtreated NIH3T3, Ptch1À/À or SufuÀ/À cells using confocal microscopy revealed no influence of phorbol esters on cilium location, morphology or frequency of appearance (Figure 2a) . To investigate cilium function in more detail, we analysed platelet-derived growth factor receptor alpha (PDGFRa) expression. PDGFRa is induced in NIH3T3 cells upon formation of primary cilia and can thus serve as an indicator of proper general cilium physiology (Schneider et al., 2005) . As shown in Figure 2b , treatment with TPA did not affect accumulation of PDGFRa protein in NIH3T3. Although these data do not preclude a Hh-specific effect of TPA on cilia, they indicate that primary cilia are unlikely the target of non-acute phorbol ester treatment.
Long-term exposure to phorbol esters is known to result in cellular depletion of several PKC isoforms. As Riobo et al. (2006a) have demonstrated the role of PKCd in Hh/Gli activation we were interested to know if PKCd mediates also the downstream inhibitory effects of TPA. Figure 3a depicts the effect of Rottlerin, a specific inhibitor of PKCd (Gschwendt et al., 1994) , on Hh signalling in SAG-stimulated Shh-L2 cells (similar effects were seen in SAG-treated NIH3T3 cells (Supplementary Figure 1) ). As a control Go¨6976, an inhibitor of PKCa and bI, was applied. Similar to depletion of cellular PKCd by TPA, pharmacological inhibition of this isoform by Rottlerin resulted in inhibition of signalling. The control PKCa/bI inhibitor was ineffective.
Furthermore, we analysed Gli1 expression in SufuÀ/À cells treated with TPA, Rottlerin, Go¨6976 or FSK ( Figure 3b ). As expected of TPA and Rottlerin having a common target, both caused a reduction in target gene expression, indicating pathway inhibition. FSK, which inhibits signalling at the level of GLI proteins (Kaesler et al., 2000; Pan et al., 2006) , was included as a positive control for downstream inhibition. Interestingly, blocking the activity of the calcium-dependent PKC isozymes a and bI with Go¨6976 resulted in an increase in Gli1 expression in these cells (Neill et al., 2003) . To confirm that PKCd was indeed downregulated in the analysed cells, we performed immunoblotting of protein extracts from TPA-treated cell lines and verified that in all cases The results obtained so far demonstrated that inhibition by TPA occurs downstream of Sufu, thus suggesting the Gli transcription factors as putative TPA targets. We transiently expressed GLI1 (Kogerman et al., 1999) or the constitutively active variant of GLI2, DN-GLI2 (Regl et al., 2002) , together with a Hh reporter plasmid (Sasaki et al., 1997) and a Renilla luciferase plasmid for normalization in NIH3T3 cells. After the cells had reached confluency (to provide all accessory functions such as primary cilia), they were treated with TPA, Rottlerin, FSK or the Mek1 inhibitor PD98059 (Figure 3c ). As expected for compounds directly acting at the level of Gli, FSK and PD98059 treatment Riobo et al., 2006a) inhibited GLI1 and GLI2-mediated transcription. However, neither TPA nor Rottlerin was able to block transcription of any of the GLI variants, showing that these compounds do not act directly on GLI and imply that the observed inhibitory effects are likely exerted upstream of GLI1/GLI2. Data on the lack of effect of TPA on full-length GLI2 are depicted in Supplementary  Figure 2 . However, it should be noted that the overexpression of Gli proteins might override regulatory mechanisms which usually control endogenous Gli. Because no effect on GLI was detected, the results strongly suggest that the inhibition of the Hh pathway by TPA is not mediated through Mek1 kinase. This conclusion was confirmed in a second experiment in which NIH3T3 cells were transfected with Hh reporter plasmids and a dominant-active Mek1 expression Protein kinase Cd in Hedgehog signal transduction M Lauth et al construct (Okazaki and Sagata, 1995) . If the depletion of PKCd by TPA resulted in inactivation of Mek1 and subsequent Gli degradation Riobo et al., 2006a ; Supplementary Figure 3) , overexpression of dominant-active Mek1 should rescue this Mek1 inhibition and TPA treatment should not result in pathway inhibition. As shown in Figure 3d , TPA potently inhibits Hh signalling irrespective of the presence of dominant active Mek1, suggesting that the TPA/PKCd effect is independent of Mek1 kinase and that the phorbol ester-induced GLI activation (which is reported to be Mek1-dependent; Riobo et al., 2006a) and the downstream pathway inhibition (which is Mek1-independent, data shown here) are two distinct processes. Alternatively, the reason why PD98059 could inhibit PKCd-induced Gli activation (Riobo et al., 2006a) is because Mek1 acts downstream of PKCd. These findings are in agreement with the lack of effect of TPA on Mek1-mediated superactivation of transfected GLI1 (Supplementary Figure 4) . After focusing on the level at which phorbol esters and Hh signalling functionally interact, we analysed the mechanism of pathway activation in three human cancer cell lines. The two prostate cancer cell lines 22Rv1 and DU145 as well as the pancreatic adenocarcinoma cell line PANC1 express numerous Hh pathway components including GLI1, indicative of active signalling (Figure 4a) .
To dissect the Hh pathway in these cell lines, they were exposed to Cyclopamine, TPA or FSK for 48 h (Figure 4b ). All three cell lines did not respond to inhibition of Smo by Cyclopamine, suggesting activation downstream of Smo, which is in line with previous reports (Sanchez et al., 2004; Bhatia et al., 2006) . Treatment with FSK resulted in a reduction in GLI1 mRNA levels in DU145 and 22Rv1 cells, but not in PANC1 cells, suggesting a novel mechanism in which tumour cells could activate GLI signalling by escaping PKA-mediated inhibition. In addition, a differential responsiveness towards TPA was found. Whereas Hh/ GLI signalling in DU145 and PANC1 cells was inhibited by phorbol ester treatment, no reduction in GLI1 expression could be detected in 22Rv1 cells. These results suggest downstream pathway activation affecting a step between SUFU and GLI in DU145 and PANC1 and activation at the level of GLI in 22Rv1 cells. An immunoblot showing equal PKCd depletion in these three cell lines is depicted in Figure 4c . Expression levels of additional Hh target genes are provided in Supplementary Figure 5 .
In summary, we demonstrated the functional requirement for PKCd activity in a Hh signal transduction step from Sufu to the Gli transcription factors. Cellular PKCd depletion by TPA treatment or pharmacological inhibition blocked signal transduction at this step. Furthermore, this inhibition process occurs upstream of and is independent of the Mek1 kinase which directly affects Gli activity (Supplementary Figure 6) . Finally, we made use of phorbol esters as a tool to fine-map activation points within the Hh pathway and demonstrate that human tumour cells have acquired downstream activating alterations at distinct levels of the Hh pathway. Protein kinase Cd in Hedgehog signal transduction M Lauth et al
